SCHEMBL2660780

SCHEMBL2660780

CCCN1Cc2nc3c(-c4ccccc4C)cccc3c(N)c2C1=O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GABRG2 P18507 4/20 0.42
▸ GABRB3 P28472 4/20 0.42
▸ GABRA2 P47869 4/20 0.42
▸ LMNA P02545 1/20 0.38
▸ PARP1 P09874 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ PARP2 Q9UGN5 1/20 0.38
▸ HRH4 Q9H3N8 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ MAPK10 P53779 1/20 0.36
▸ GAA P10253 1/20 0.35
▸ BRD4 O60885 1/20 0.34
▸ LCK P06239 1/20 0.34
▸ BTK Q06187 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ TLR8 Q9NR97 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2655382 0.93 LMNA (0.38) GABRG2GABRB3GABRA2LMNAPARP1
SCHEMBL9684592 0.90 PARP1 (0.42) GABRG2GABRB3GABRA2LMNAPARP1
SCHEMBL4922388 0.90 LCK (0.47) GABRG2GABRB3GABRA2LMNAPARP1
SCHEMBL2661290 0.90 GABRG2 (0.46) GABRG2GABRB3GABRA2LMNAPARP1
SCHEMBL2660012 0.88 LMNA (0.38) LMNAPARP1HTTPARP2ALDH1A1
SCHEMBL2660713 0.88 HRH4 (0.42) GABRG2GABRB3GABRA2LMNAPARP1
SCHEMBL4924455 0.88 GABRG2 (0.36) GABRG2GABRB3GABRA2LMNAPARP1
SCHEMBL2661191 0.87 LMNA (0.35) GABRG2GABRB3GABRA2LMNAPARP1
SCHEMBL4915502 0.87 LMNA (0.36) GABRG2GABRB3GABRA2LMNAPARP1
SCHEMBL4919219 0.87 HTT (0.36) GABRG2GABRB3GABRA2LMNAPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF GABRG2 592/4885GABRB3 332/4885GABRA2 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback